Clinical Trial Search

Primary: MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery — 333.7; 105.1 fmol/mg of proteins — p=0.09

Primary: Change in Resting vs. Peak Heart Rate Systolic Blood Pressure (SBP) From Baseline to Week 8 After a Missed Dose — 2.58; 8.26 mmHg

Primary: Change From Baseline (Day -1) in Overall Lane Position Variability (LPV) on Day 16 (Tmax) — -0.10; 0.15; 0.15; 0.16 feet

Primary: Number of Patients With Complete Remission — 8; 8; 34; 31 Participants

Primary: International Restless Legs Syndrome (IRLS) Total Score — -8.9; -4.0 Scores on a scale

Primary: Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 — -71.1; -68.4 Percentage change in betaCTX

Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — -0.027; -0.006; -0.044; -0.033 Liters

Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885

Primary: Positive and Negative Syndrome Scale (PANSS) Total Score Change From Baseline — 1.40; 4.51; -8.79 Points on a scale

Primary: Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5 — -9.8; -2.9; -5.0; -6.5 mm Hg

Primary: Response to Treatment (ACR20) in Adult Patients With Established Rheumatoid Arthritis (RA) — 17; 2; 27; 2 Participants

Primary: Maintenance of Wakefulness Test (MWT) — 23.3; 27.9; 29.3; 27.6 Minutes — p=<0.0001

Primary: HIV-1 RNA Level — 1.2; 1.7 copies/mL — p=0.546

Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion